677 related articles for article (PubMed ID: 9077564)
1. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
Jankowski RA; Ildstad ST
Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
[TBL] [Abstract][Full Text] [Related]
2. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
3. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
4. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
5. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment.
Gammie JS; Li S; Colson YL; Demetris AJ; Neipp M; Ildstad ST; Pham SM
Exp Hematol; 1998 Sep; 26(10):927-35. PubMed ID: 9728927
[TBL] [Abstract][Full Text] [Related]
6. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
9. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
11. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
Colson YL; Zadach K; Nalesnik M; Ildstad ST
Transplantation; 1995 Nov; 60(9):971-80. PubMed ID: 7491703
[TBL] [Abstract][Full Text] [Related]
12. Alloresistance to K locus class I-mismatched bone marrow engraftment is mediated entirely by CD4+ and CD8+ T cells.
Hayashi H; LeGuern C; Sachs DH; Sykes M
Bone Marrow Transplant; 1996 Aug; 18(2):285-92. PubMed ID: 8864436
[TBL] [Abstract][Full Text] [Related]
13. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
Shizuru JA; Jerabek L; Edwards CT; Weissman IL
Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
[TBL] [Abstract][Full Text] [Related]
14. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
Sykes M; Sharabi Y; Sachs DH
Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
[TBL] [Abstract][Full Text] [Related]
15. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST
J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385
[TBL] [Abstract][Full Text] [Related]
16. Tolerance induction through megadose bone marrow transplantation with two-signal blockade.
Lee EN; Lee J; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Kwon CH; Joh JW; Kim SJ
J Surg Res; 2006 Jan; 130(1):102-9. PubMed ID: 16183077
[TBL] [Abstract][Full Text] [Related]
17. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
18. Facilitating cells enable engraftment of purified fetal liver stem cells in allogeneic recipients.
Gaines BA; Colson YL; Kaufman CL; Ildstad S
Exp Hematol; 1996 Jul; 24(8):902-13. PubMed ID: 8690049
[TBL] [Abstract][Full Text] [Related]
19. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
20. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]